Repros Therapeutics Inc. (NASDAQ:RPRX) shares were up 3.9% during mid-day trading on Thursday . The stock traded as high as $2.15 and last traded at $2.12, with a volume of 87,080 shares. The stock had previously closed at $2.04.

Separately, Zacks Investment Research cut Repros Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 13th. One equities research analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. Repros Therapeutics currently has an average rating of “Hold” and a consensus target price of $2.00.

The company’s market capitalization is $53.74 million. The firm’s 50-day moving average is $1.83 and its 200 day moving average is $1.59.

Repros Therapeutics (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, August 9th. The company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. On average, equities analysts predict that Repros Therapeutics Inc. will post ($0.70) EPS for the current year.

Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include Androxal and Proellex. The Company’s primary product candidate Androxal is a single isomer of clomiphene citrate and an orally active proprietary small molecule compound, which is developed for the treatment of secondary hypogonadism in overweight men.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.